Filing Details
- Accession Number:
- 0001179110-21-006974
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-23 16:05:36
- Reporting Period:
- 2021-06-21
- Accepted Time:
- 2021-06-23 16:05:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 815094 | Abiomed Inc | ABMD | Surgical & Medical Instruments & Apparatus (3841) | 042743260 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1286370 | R Michael Minogue | C/O Abiomed, Inc., 22 Cherry Hill Drive Danvers MA 01923 | Chairman, President, Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock $.01 Par Value | Acquisiton | 2021-06-21 | 25,000 | $23.15 | 236,635 | No | 4 | M | Direct | |
| Common Stock $.01 Par Value | Disposition | 2021-06-21 | 19,657 | $325.16 | 216,978 | No | 4 | S | Direct | |
| Common Stock $.01 Par Value | Disposition | 2021-06-21 | 5,343 | $326.04 | 211,635 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-06-21 | 25,000 | $0.00 | 25,000 | $23.15 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 60,000 | 2014-05-14 | 2023-05-14 | No | 4 | D | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock $.01 Par Value | 52,555 | Indirect | By Trust - A |
| Common Stock $.01 Par Value | 73,745 | Indirect | By Trust - B |
| Common Stock $.01 Par Value | 32,810 | Indirect | By Trust - C |
| Common Stock $.01 Par Value | 655 | Indirect | By Trust - D |
| Common Stock $.01 Par Value | 38,560 | Indirect | By Trust - E |
| Common Stock $.01 Par Value | 85,040 | Indirect | By Trust - F |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | $21.55 | 2015-05-14 | 2024-05-14 | 0 | 85,000 | Direct |
| Common Stock | Stock Option (right to buy) | $66.25 | 2016-05-13 | 2025-05-13 | 0 | 35,000 | Direct |
| Common Stock | Stock Option (right to buy) | $99.62 | 2017-05-24 | 2026-05-24 | 0 | 30,500 | Direct |
| Common Stock | Stock Option (right to buy) | $134.51 | 2018-05-15 | 2027-05-15 | 0 | 33,000 | Direct |
| Common Stock | Stock Option (right to buy) | $381.97 | 2019-05-16 | 2028-05-16 | 0 | 30,000 | Direct |
| Common Stock | Stock Option (right to buy) | $266.39 | 2020-05-30 | 2029-05-30 | 0 | 50,000 | Direct |
| Common Stock | Stock Option (Right to Buy) | $223.90 | 2021-05-29 | 2030-05-29 | 0 | 20,898 | Direct |
| Common Stock | Stock Option (Right to Buy) | $283.88 | 2022-05-25 | 2031-05-25 | 0 | 30,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2024-05-14 | 0 | 85,000 | Direct |
| 2025-05-13 | 0 | 35,000 | Direct |
| 2026-05-24 | 0 | 30,500 | Direct |
| 2027-05-15 | 0 | 33,000 | Direct |
| 2028-05-16 | 0 | 30,000 | Direct |
| 2029-05-30 | 0 | 50,000 | Direct |
| 2030-05-29 | 0 | 20,898 | Direct |
| 2031-05-25 | 0 | 30,000 | Direct |
Footnotes
- These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- Exercise of stock options pursuant to reporting owners 10b5-1 plan.
- Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- This price represents the sale price of the transactions on the reported date at $325.1555. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- This price represents the sale price of the transactions on the reported date at $326.0398. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
Billionaire Hedge Funds
